٠.	Z .
Date Mailed:	January 5 , 2002

~.						
She	:ct	1	0	ľ	6	

	,	-
FOR	M 1449*	
	INFORM	ATION DISCLOSURE STATEMEN
	017E	
	<u> </u>	IN AN APPLICATION
1	IAM 9 4 9009 A	

		\Box	
Docket Number:	Application Number:	NI	-;
12152.48US11	09/957,434	盟	. (
Applicant: Yiv et al.		<u> </u>	7
Filing Date: 9/19/01	Group Art Unit: 1614	-0%	7,

PARADENIA (PARAMETER)			U.S. PATENT DOCUMEN	rs			
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS		DATE OPRIATE
M.C.H	Re 36,256	7/20/1999	Spada et al.				
	3,850,939	11/26/1974	Elslager et al.				
	3,970,725	7/20/1976	Tugukuni et al.				
	4,938,949	7/3/1990	Borch et al.				
	4,992,271	2/12/1991	Fernandes et al.	—			
	5,069,906	12/3/1991	Cohen et al.				
	5,198,333	3/30/1993	Dewanckele et al.				
	5,314,685	5/24/1994	Tyle et al.				
	5,411,963	5/2/1995	Dreikorn et al.				
	5,449,678	9/12/1995	Pines et al.				
	5,457,105	10/10/95	Barker				
	5,468,898	11/21/1995	Huang et al.	1			
	5,712,237	2/24/1998	Myers et al.	-		·	
M·C·H	5,792,771	8/11/1998	App et al.				
,							
		FC	REIGN PATENT DOCUM	ENTS			
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANS	LATION
				:		YES	NO
MCH S	0 082 385	12/4/1982	Europe				
	*WO 94/03157	7/23/1993	PCT				
*	WO 95/07696	8/30/1994	PCT				
	² WO 95/15758	12/8/1994	PCT				
	*WO 95/24190	3/6/1995	PCT		,		
C	• WO 95/31969	4/28/1995	PCT	F			
(· WO 96/06616	8/29/1995	PCT			DEAR	
	'WO 96/22976	12/22/1995	PCT			RECE	VED
	WO 96/33745	4/17/1996	PCT			JAN 3 0	2002
M.C.H	WO 96/39143	6/4/1996	PCT		_		

		<u></u>	
EXAMINER	DATE CONSIDERED	191	05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

^{*}Substitute Disclosure Statement Form (PTO-1449)

	٠,		
Date	Mailed:	January	_ 2002



FORME	NFORMATIC	N DISCLOS	URE STATEM	ENT	Docket 12152.4	Number:		Applica 09/957,	ution Number: 434	
o / 2002	C\ A: IN	AN APPLIC	ATION		Applica	nt: Yiv et al.				
JAN 2 4 2002	OD j البر (Use s	everal sheets it	f necessary)		Filing D	Date: 9/19/01		Group A	Art Unit: 1614	
RUPHIT	3 (32)		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,					<u> </u>		
M·C·H	°WO 96/4011	3	6/7/1996	PCT						
1	* WO 96/4011	6 \	6/5/1996	РСТ				,		
	° WO 96/4064	8	6/4/1996	PCT						
	WO 98/3898	34	3/4/1998	PCT						
9	WO 98/5128	34	5/12/1998	PCT			/	<u> </u>		
	*WO 99/1032	25	8/4/1998	PCT				,	<u> </u>	1
M·C·H	WO 99/3606	53	2/20/1998	PCT					 	
11 617	· · · · ·	ОТНІ	ER DOCUMEN'	TS (Including Author, T	itle, Date,	Pertinent Page	es, Etc.)			
M·c·H	٥		al., <i>J. American I</i> AVMA Panel o	eterinary Medicine Asso f Euthanasia	ociation, \	/ol. 202, No. 4	, рр. 229-	249, 1993	}	
M.C.1+	•			t Dis Clin North Am, 19 es in HIV-Infected Perso		48				
	•	Brassinne et	al., <i>JNCI</i> , Vol. 7	O, No. 6, pp. 1081-1087.		10 do			•	
			ctivity of a Wate	r-Insoluble Compound	Entrappéd	in Liposomes	on L1210	Leukemt	a in Mice	
M.C.H		Contraceptiv	e Effect of Spen	n-Agglutinating Monoc	onal Anti	bodies in Rabt	oits			
Mc.H	•		Contraception, lee Testing of Vag	1998, 58:51-60 ginal Agents in Rabbits						
				ol., 3, No. 1, pp. 1-7		10 d	a L	2		
M.C.H	,	Chantler E.,	Brit Fam Plann,							
700 011	,		micides: some c	cal Research, Vol. 9, No	. 1, pp. 87	-93, 1992				······································
M·C·H M·C·H				ery Systems: Formulation			Evaluation	n of an In	vestigational L	ipophilic
M·C·1+				cal Research, Vol. 12, N proving Drug Dissolution				ınd Bioph	narmaceutical A	spects
M-C·H	2		•	ica Scandinavica, 51(3) nalogues of HEPT and I				-		
m-C+H	•			hem., 41:191-198						
Mich				ctivity of Novel 2,3-Dihy	/dro7H-th	iazolo[3,2-α]p	yrimidin-	7-ones		
	^			264, pp. 1415-1421 Inscriptional Activation I	n Resnons	e to IENs and	Other Ext	Q acettular	Signaling Proto	ins
				of Reproduction, 53(5):1						
MCH MC.H			(CD11b/CD18)	is the Primary Adhesive		tein Complex	Involved i	_	phil-Mediated I	
M.C.H	خ			Reproduction, 4(7), pp. 6 ated Complexes of bis(c		fienyl)vanadiu	ım(IV)	•	IAN 3 0 2	
		_							ICE OF PETI	
EXAMINER				DATE	CONSI	DERED	1/19	105	· · · · · · · · · · · · · · · · · · ·	
	al if reference	considered v	whether or not	citation is in conformar	ce with A	MPEP 609: di	* / - 	$+ v \sim$	tation if not in	conformance

D	A 4-1114.		2002
Date	Manca:	January	, 2002



JAN 2 4	2002 &
RADE	MARK

ORMATION DISCLOSURE STATEMENT

IN AN APPLICATION

(Use several sheets if necessary)

Docket Number:	
12152.48USI1	

Application Number:

09/957,434

Applicant: Yiv et al.

Filing Date: 9/19/01

Group Art Unit: 1614

		- 1 1000 Pt 1 Pt 1 Pt 1 Pt 1 Pt 1 Pt 1 Pt
M.C.H	Ť	D'Cruz et al., 1998, Biology Reproduction, 58:1515-1528
1, 7, 14		Spermicidal Activity of Metallocene Complexes Containing Vanadium(IV) in Humans
	9 "	
		Aryl Phosphate Derivatives of Bromo-Methoxy-Azidothymidine Are Dual-Function Spermicides with Potent Anti-Human Immunodeficiency Virus
		D'Cruz et al., 1999, Biology of Reproduction, 60:1419-1428
		Novel Derivatives of Phenethyl-5-Bromopyridylthiourea and Dihydroalkoxybenzyl-oxopyrimidine Are Dual-Function Spermicides with Potent Anti-Human Immunodeficiency Virus Activity
	•	D'Cruz et al., 1999, Biology Reproduction, 60(2), pp. 345-444
		Spermicidal activity of oxovanadium(IV) complexes of 1, 10-phenanthroline, 2,2'-bipyridyl, 5'-bromo-2hydroxyacetophenone and derivatives in humans
		D'Cruz et al., Biol. Reprod., 2001, 64(1), 51-59 Thymidine Kinase-Independent Intracellular Delivery of Bioactive Nucleotides by Aryl Phosphate Derivatives of Bromo-Methoxy Zidovudine (Compounds WHI-05 and WHI07) in Normal Human Female Genital Tract Epithelial Cells and Sperm
	Ø.	D'Cruz et al., Biology of Reproduction, Vol. 62, pp. 37-44, 2000
		Structural Requirements for Potent Human Spermicidal Activity of Dual-Function Aryl Phosphate Derivative of Bromo- Methoxy Zidovudine (Compound WHI-07)
	·	D'Cruz et al., Contraception, 1999, 59(5):319331 WHI-05, a Novel Bromo-methoxy Substituted Phenyl Phosphate Derivative of Zidovudine, Is a Dual-Action Spermicide with Potent Anti-HIV Activity
	••	D'Cruz et al., Contraception, 2000, 61(1), 69-76 Evaluation of Subchronic (13 Weeks) and Reproductive Toxicity Potential of Intravaginal Gel-Microemulsion Formulation of Dual-Function Phenyl Phosphate Derivative of Bromo-Methoxy Zidovudine (Compound WHI-05) in B ₆ C ₃ F ₁ Mice
		D'Cruz et al., Molecular Human Reproduction, Vol. 5, No. 5, pp. 421-432, 1999 Synthesis, characterization and preclinical formulation of a dual-action phenyl phosphate derivative of bromo-methoxy zidovudine (compound WHI-07) with potent anti-HIV and spermicidal activities.
	r	de Jong, <i>Therapie</i> , 1999, 54:11-14 The safety of pharmaceutical excipients
	:	Diehl et al., J. Virol, 1995, 69:2328-2332 Longitudinal Assessment of Feline Immunodeficiency Virus Kinetics in Plasma by Use of a Quantitative Competitive Reverse Transcriptase PCR
	,	Digenis GA, et al., Pharm Dev Technol, 1999;4:421-30
		Novel Vaginal Controlled-Delivery Systems Incorporating Coprecipitates of Nonoxynol-9
	o	Eccleston GM, In: Swarbrick J. Boylan JC, eds. Encyclopedia of Pharmaceutical Technology, NY, Marcel Dekker, 1992:375-421 Microemulsions
	و	Eckstein et al., J. Reprod Fertil., 1969, 20:85-93 Comparison of Vaginal Tolerance Tests of Spermicidal Preparations in Rabbits and Monkeys RECEIVED
M.C.H	ų	Fischer et al., Science, Vol. 253, No. 5018, pp. 401-406, 1991 Protein Tyrosine Phosphatases: A Diverse Family of Intracellular and Transmembrane Enzymes JAN 3 0 2002
		Folkman, Journal of the National Cancer Institute, Vol. 82, No. 1, pp. 46 What is the Evidence that Tumors are Angiogenesis Dependent? NO Don to OFFICE OF PETITIONS
M.C.H	•	Furuse K, et al., <i>J Pharmacobiodyn</i> , 1983;6:35972 Studies on Spermicidal Activity of Surfactants
M·C·H		Greene et al., ARch Virol, 1993, 133:51-62 Extensive sequence variation of feline immunodeficiency virus env genes in isolates from naturally infected cats
M·C·H		Hamawy et al., 1995, Cellular Signalling, 7(6):535544 Protein Tyrosine Phosphorylation as a Mechanism of Signalling in Mast Cells and Basophils

	<i>(</i> ()			A
EXAMINER	OB	DATE CONSIDERED //	19	05
				web election if not in conformance

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw fine through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.



FORM 1997 PINCORMATION DISCLOSURE STATEMENT	Docket Number: 12152.48USI1	Application Number: 09/957,434	
JAN 2 4 2002 E IN AN APPLICATION	Applicant: Yiv et al.		
() (Lice several cheets if necessary)	Filing Date: 9/19/01	Group Art Unit: 1614	

MADRIANS			
		Heidin, Cell, Vol. 80, pp. 213-223, 1995	
M-C-14		Dimerization of Cell Surface Receptors in Signal Transduction	
	-	Helenious A, et al., Biochem Biophys Acta, 1975;415:29-79 Solubilization of Membranes by Detergents	
	•	Hira et al., International Journal of STD & AIDS, Vol. 8, pp. 243-250, 1997	
		Condom and nonoxynol-9 use and the incidence of HIV infection in serodiscordant couples	s in Zambia
	•	Hooten TM, et al., <i>JAMA</i> , 1991;265:64-9 Escherichia coli Bacteriuria and Contraceptive Method	
	••	Hunter, Cell, Vol. 58, pp. 1013-1015, 1989	
		Protein-Tyrosine Phosphatases: The Other Side of the Coin	DECEIVED
	,	Hynes et al., Journal of Heterocyclic Chemistry, Vol. 25, No. 4, pp. 1173-1177, 1988	RECEIVED
-		Direct Synthesis of 2,4-Diaminoquinazolines from 2-Fluorobenzonitriles	1011 2 0 2002
	7	Hynes et al., Journal of Heterocyclic Chemistry, Vol. 28, No. 5, pp. 1357-1363, 1991	JAN 3 0 2002
		Further Studies on the Synthesis of Quinazolines from 2-Fluorobenzonitriles	OFFICE OF DETITIONS
			OFFICE OF PETITIONS
<u> </u>		International Search Report, PCT/US 00/07066, 8/11/2000	
]	٥	International Search Report, PCT/US 00/07419, 9/7/2000	
	ð	Katz et al., Proc. Nat'l, Acad. Sci U.S.A., 1991, 88:1082510829 Antiviral activity of 1-docosanol, an inhibitor of lipid-enveloped viruses including herpes si	implex
	3	Klagsbrun et al., Current Biology, Vol. 3, No. 10, pp. 699-702, 1993	
		VEGF/VPF: the angiogenesis factor found?	
		Kreiss et al., JAMA, Vol. 268, pp. 477-482, 1998	
		Efficacy of Nonoxynol 9 Contraceptive Sponge Use in Preventing Heterosexual Acquisition	n of HIV in Nairobi Prostitutes
		Kulig JW, Ped Clinic North Am, 1989;36:717-30	
		Adolescent Contraception: Nonhormonal Methods	
	•	Kumar et al., 1994, J. Med. Chem., 37:4297-4306 Synthesis, in Vitro, Biological Stability, and Anti-HIV Activity of 5-Halo-6-alkoxy(or azido deoxythymidine Diastereomers as Potential Prodrugs to 3'-Azido-3'-deoxythymidine (AZT)	o)-5,6dihydro-3'-azido-3'-
	U	Lundberg, J. Pharm Pharmacol, 1997, 49:16-21 A Submicron Lipid Emulsion Coated with Amphipathic Polyethylene Glycol for Parenteral (Taxol)	Administration of Paclitaxel
	•	Mai et al., 1997, J. Med. Chem., 40(10):1447-1454	
		Dihydro(alkylthio)(naphthylmethyl)oxopyrimidines: Novel Non-Nucleoside Reverse Trans Series	scriptase Inhibitors of the S-DABO
	D.	Malaviya et al., 1999, J. Bio. Chem., 274(38) 2702827038	
	,	Targeting Janus Kinase 3 in Mast Cells Prevents Immediate Hypersensitivity Reactions and	Anaphylaxis
	•	McGuigan et al., 1993, J. Med. Chem., 36:1048-1052 Intracellular Delivery of Bioactive AZT Nucleotides by Aryl Phosphate Derivatives of AZT	
	-	Mendez F, et al., Contraception, 1986;34:353-62 Use Effectiveness of a Spermicidal Suppository Containing Benzalkonium Chloride	
	•	Murhammer et al., Biotechnology Progress, 1990, Vol. 6, pp. 391-397	
		Sparged Animal Cell Bioreactors: Mechanism of Cell Damage and Pluronic F-68 Protectio	n
	- 6	Naria et al., Clin. Cancer Res., 1998, 4:1405-1414	and the processing of the second
		4-(3'-Bromo-4'hydroxylephenyl)-amino-6,7dimethoxyquinazoline: A Novel Quinazoline I Activity against Human Glioblastoma Cells	Jerivative with Potent Cytotoxic
M-C. 1+		Narla et al., Clin. Cancer Res., 1998, 4:2463-2471 Inhibition of Human Glioblastoma Cell Adhesion and Invasion by 4-(4'-Hydroxylphenyl)-a	mino-6. Himethoxyouinazoline
		minution of Human Onobiasiona Cen Asiasion and Invasion by 4-(4-1) dioxylphonyl-a	

	\sim			
EXAMINER		DATE CONSIDERED /	/19	105
EYAMINED:	Initial if reference considered, whether	or not citation is in conformance with MPEP 609: draw	line t	hrough citation if not in conformance

and not considered. Include copy of this form for next communication to the Applicant.

Date Mailed: January, 2002		Sheet 5 of 6	긆	
FORM ON P INFORMATION DISCLOSURE STATEMENT	Docket Number: 12152.48USII	Application Number: 09/957,434	SHCE	JAN
IN AN APPLICATION	Applicant: Yiv et al.		Ħ	.9
(Use several sheets if necessary)	Filing Date: 9/19/01	Group Art Unit: 1614	R 16	ს /
PADEMARK) (2/000	b02
L (WHI DI21) and 4 (2) Promo d'hydrovylah	anul\ amino 67 dimethovyouingzoline	(WHI-DISA)	_	

RADEMARIE		00/23
M·C·H	Nerukar et al., Pharma	Bromo-4'hydroxylphenyl)-amino-6,7dimethoxyquinazoline (WHI-P154) sceutical Research, 1996, 13:528534 s to Enhance the Permeability of Peptides Through Caco-2 Cells by Inhibition of an Apically Polarized
	Niruthisard et al., Sexu	nally Transmitted Diseases, Vol. 18, No. 3, pp. 176-179 Nonoxynol-9 Use on the Vaginal and Cervical Mucosa
M·C·H	/1	Chem. Pharm. Bull., 38(6):1591-1595 Agents. I. Synthesis of Some Quinazoline Derivatives
	Studies on Cardiotonic	Pharm Bull., 1990, 38:1591-1595 Agents. I. Synthesis of Some Quinazoline Derivatives Duflicate
M·C·14	Superinfection of Cats	t. Hum Retroviruses, 1994, 10:173946 with Feline Immunodeficiency Virus Subtypes A and B egister, 1980;45:82014-49
		Bio. Chem., 268(3):1749-1756 2*-independent Isozymes of Protein Kinase C Mediate Exocytosis in Antigen-stimulated Rat Basophilic
	Patton DL, et al., Sex 7 The Vaginal Microflor	Trans Dis, 1996, 23:489-93 a of Pig-Tailed Macaques and the Effects of Chlorhexidine and Benzalkonium on this Ecosystem
	Pawson, Nature, Vol. Protein modules and si	373, No. 6515, pp. 573580, 1995 gnalling networks
		ol. 359, No. 6398, pp. 845-848, 1992 rowth factor is a potential tumor angiogenesis factor in human gliomas <i>in vivo</i>
	· ·	et Biophysica Acta, Vol. 1136, pp. 35-43, 1992 rotein tyrosine phosphatases
		maceutics, No. 27, pp. 335-348, 1985 delivery systems: assessment of the efficiency of emulsification
		r Gynecol, 1999, 93:896-903 eness of Two Spermidides: A Randomized Trial
	The Toxicity and Loca	If: 1972,5:4237 I Effects of the Spermicide Nonoxynol 9 Ophys. Res. Commun., 1984, 121:12633 I RNA Dependent DNA Polymerase of a New Human T Lymphotropic Retrovirus (Lymphadenopathy
유 .	Ritschel, Methods and Microemulsions for In	Findings in Experimental and Clinical Pharmacology, 1993, 13:205-20 aproved Peptide Absorption from the Gastrointestinal Tract
OFFICE (A dosing study of non-	STD & HIV, 1993;4:16570 exproise and genital irritation igl J Med, 1998;339:50410
m	A Controlled Trial of I Rosenstein IJ, et al. J J	Nonoxynol 9 Film to Reduce Mail-to-Female Transmission of Sexually Transmitted Diseases **Nonoxynol 9 Film to Reduce Mail-to-Female Transmission of Sexually Transmitted Diseases **Nonoxynol 9 Film to Reduce Mail-to-Female Transmission of Sexually Transmitted Diseases **Nonoxynol 9 Film to Reduce Mail-to-Female Transmission of Sexually Transmitted Diseases **Nonoxynol 9 Film to Reduce Mail-to-Female Transmission of Sexually Transmitted Diseases **Nonoxynol 9 Film to Reduce Mail-to-Female Transmission of Sexually Transmitted Diseases **Nonoxynol 9 Film to Reduce Mail-to-Female Transmission of Sexually Transmitted Diseases **Nonoxynol 9 Film to Reduce Mail-to-Female Transmission of Sexually Transmitted Diseases **Nonoxynol 9 Film to Reduce Mail-to-Female Transmission of Sexually Transmitted Diseases **Nonoxynol 9 Film to Reduce Mail-to-Female Transmission of Sexually Transmitted Diseases **Nonoxynol 9 Film to Reduce Mail-to-Female Transmission of Sexually Transmitted Diseases **Nonoxynol 9 Film to Reduce Mail-to-Female Transmission of Sexually Transmitted Diseases **Nonoxynol 9 Film to Reduce Mail-to-Female Transmission of Sexually Transmitted Diseases **Nonoxynol 9 Film to Reduce Mail-to-Female Transmission of Sexually Transmitted Diseases **Nonoxynol 9 Film to Reduce Mail-to-Female Transmission of Sexually Transmitted Diseases **Nonoxynol 9 Film to Reduce Mail-to-Female Transmission of Sexually Transmitted Diseases **Nonoxynol 9 Film to Reduce Mail-to-Female Transmission of Sexually Transmitted Diseases **Nonoxynol 9 Film to Reduce Mail-to-Female Transmission of Sexually Transmitted Diseases **Nonoxynol 9 Film to Reduce Mail-to-Female Transmission of Sexually Transmitted Diseases **Nonoxynol 9 Film to Reduce Mail-to-Female Transmission of Sexually Transmitted Diseases **Nonoxynol 9 Film to Reduce Mail-to-Female Transmission of Sexual Property Transmitted Diseases **Nonoxynol 9 Film to Reduce Mail-to-Female Transmission of Sexual Property Transmitted Diseases **Nonoxynol 9 Film to Reduce Mai
	Immunodeficiency Vie	us Type 1 Th & Differentiation, Vol. 2, pp. 59-65, 1991
	Molecular Characteriz	ation of Protein Tyrosine Phosphatases rtil, 1941, 6:134-137 Traction the Securicidal Action of Chemical Contracentives
M.C.H	Schill WB, et al., Andr	Testing the Spermicidal Action of Chemical Contraceptives ologia, 1981;13:42-9 an Spermatozoa in the Presence of the Spermicide Nonoxinol-9 and a Vaginal Contraceptive Containing

	Ani .		1		
EXAMINER	14-7	DATE CONSIDERED	1/19	1/05	
	,				

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

(Use several sheets if necessary)



Group Art Unit: 1614

Filing Date: 9/19/01

FORM 1449* O 1 P INFORMATION DISCLOSURE STATEMENT	Docket Number: 12152.48USI1	Application Number: 09/957,434
in an application	Applicant: Yiv et al.	

THE TRADENA	RIV SEELY	
- CAULT		Nonoxinol-9
MCH		Schlessinger et al., Neuron, Vol. 9, pp. 383-391, 1992
NIGH	t	Growth Factor Signaling by Receptor Tyrosine Kinases
	,	Schwinn et al., Journal of Radioanalytical and Nuclear Chemistry, Vol. 232, Nos. 1-2, pp. 35-37, 1998
		The effects of a thio-containing quinazolinedione derivative (MECH) on the lipid oxidation in bilayer liposomes
	 -	, Stafford MK, J Acquir Immune Defic Syndr Hum Retrovirol, 1998;17:32731
		Safety Study of Nonoxynol-9 as a Vaginal Microbicide: Evidence of Adverse Effects
	,	Sutherland, Trends in Biology, 1998, Vol. 16, pp. 41-46
		Novel and Established Applications of Microbial Polysaccharides
	•	Taylor et al., Annual Review, Cell Biology, Vol. 8, pp. 429-462, 1992
Ì		Structural Framework for the Protein Kinase Family
	-	t Tellier et al., Veterinary Microbiology, 1997, Vol. 57, p. 1-11
		Development of FIV-specific Cytolytic T-lymphocyte Responses in Cats Upon Immunisation with FIV Vaccines
		Tenjaria, Crit. Rev. Ther. Drug Carrier, 1999, 16:461-521
		Microemulsions: An Overview and Pharmaceutical Applications Trussell J. et al. Stud Fam Plann, 1987;18:23783
1	,	Contraceptive Failure in the United States: A Critical Review of the Literature
	92	Uckun et al., 1985, Blut, 50:19-23
	y	Ex vivo elimination of neoplastic T-Cells from Human Marrow Using an Anti-M, 41,000 Protein Immunotoxin: Protentiation by ASTA Z7557
		Vig et al., 1998, Bioorganic & Medicinal Chemistry Letters 8:1461-1466
		5-Alkyl-2-[(Methylthiomethyl)Thio]-6-(Benzyl)-Pyrimidine-4-(1H)-Ones as Potent Non-nucleoside Reverse Transcriptase Inhibitors of S-DABO Series
		Vig et al., 1998, Bioorganic & Medicinal Chemistry, 6:1789-1797
	9,	Rational Design and Synthesis of Phenethyl-5-bromopyridyl Thiourea Derivatives as Potetn Non-nucleoside Inhibitors of HIV Reverse Transcriptase
	٥	Weir et al., Genitourin Med., Vol. 71, pp. 78-81, 1995
}		Nonoxynol-9 use, genital ulcers, and HIV infection in a cohort of sex workers
	3	Woodcock et al., Cancer Res., 1990, 50:4199-4203
		Reveral of the Multidrug Resistance Phenotype with Cremophor EL, a Common Vehicle for Water-insoluble Vitamins and Drugs
	,	Yiv et al., Abstracts of Papers American Chemical Society, Vol. 217, pp. 148, 1999
		Microemulsion, liposome and mixed micellar formulations for a poorly water soluble quinazoline derivative
Λ	0	Yiv et al., Abstracts of Papers American Chemical Society, Vol. 217, No. 12, pp. 015, 1999
MC.H		Development of a vaginal cream for a novel anti-HIV spermicide.

RECEIVED

JAN 3 0 2002

OFFICE OF PETITIONS



PATENT TRADEMARK OFFICE

EXAMINER DATE CONSIDERED 1/19/25

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.